Vinod H. Srihari, MD
Professor of PsychiatryCards
About
Titles
Professor of Psychiatry
Director, STEP Program; Fellow, Davenport College
Biography
Dr. Srihari's scholarly focus is on improving the outcomes of early course schizophrenia spectrum disorders. His research interests span the translational continuum from studies of etiology and pathophysiology to interventions on clinical samples, to service level innovations. As Director of the STEP Program, he leads activities that connect this research to the missions of delivering a model service (the STEP Clinic), disseminating clinical best practices (via Learning Health Networks), education and workforce development and influencing policies that support the public health mission of early Intervention for schizophrenia spectrum disorders.
In his curricular work, he has led the development and implementation of an Evidence-Based Medicine (EBM) based approach to enabling psychiatrists in training to ask, access, appraise and apply the best available scientific evidence to their practice and to audit the health of the populations they are responsible for.
Dr. Srihari also consults with academic and non-academic healthcare systems that seek to initiate or refine early intervention services for recent onset or 'first-episode' psychosis.
Appointments
Psychiatry
ProfessorPrimary
Other Departments & Organizations
- Center for Brain & Mind Health
- Connecticut Mental Health Center
- Division of Neurocognition, Neurocomputation & Neurogenetics
- Division of Public Psychiatry Research
- Global Health Studies
- Psychiatry
- Psychosis Program at Yale
- South Asian Studies
- Specialized Treatment for Early Psychosis (STEP) Program
- Yale Global Mental Health Program
- Yale Medicine
- Yale Ventures
Education & Training
- Fellow
- Yale University School of Medicine (2005)
- Resident
- Yale University School of Medicine (2003)
- MD
- University of Rochester (1998)
- BA
- University of Rochester, Biology; Religion & Classics (1994)
Research
Overview
Medical Research Interests
Biomarkers; Curriculum; Evidence-Based Medicine; Exosomes; Health Care Quality, Access, and Evaluation; Learning Health System; Mental Health Services; Mitochondrial Diseases; Oxidative Stress; Population Health; Psychotic Disorders; Public Health Informatics; Schizophrenia Spectrum and Other Psychotic Disorders
Public Health Interests
Capacity Building; Health Policy
Publications
2024
The Academic Community Early Psychosis Intervention Network: Toward building a novel learning health system across six US states
Vohs J, Srihari V, Vinson A, Lapidos A, Cahill J, Taylor S, Heckers S, Weiss A, Chaudhry S, Silverstein S, Tso I, Breitborde N, Breier A. The Academic Community Early Psychosis Intervention Network: Toward building a novel learning health system across six US states. Learning Health Systems 2024 DOI: 10.1002/lrh2.10471.Peer-Reviewed Original ResearchEarly Psychosis Intervention NetworkIntervention NetworkFirst-episode psychosisRegional clinical networksLearning health systemQuality improvement projectQuality improvement effortsCulture of continuous learningData elementsPrimary diagnosis of schizophreniaConsecutive 6-month intervalsFirst-episode psychosis clinicUsual careSuperior patient outcomesSpecialty servicesHealth systemClinical teamImplementation meetingsQuality assurance effortsImprovement projectClinical networksHealthcare systemPractice-based researchImprovement effortsQuality improvementThe anomalous effect of COVID-19 pandemic restrictions on the duration of untreated psychosis
Nicholls-Mindlin J, Hazan H, Zhou B, Li F, Ferrara M, Levine N, Riley S, Karmani S, Mathis W, Keshavan M, Srihari V. The anomalous effect of COVID-19 pandemic restrictions on the duration of untreated psychosis. BJPsych Open 2024, 10: e216. PMID: 39628123, DOI: 10.1192/bjo.2024.813.Peer-Reviewed Original ResearchTimelinePTC: Development of a unified interface for pathways to care collection, visualization, and collaboration in first episode psychosis
Mathis W, Ferrara M, Cahill J, Karmani S, Tayfur S, Srihari V. TimelinePTC: Development of a unified interface for pathways to care collection, visualization, and collaboration in first episode psychosis. PLOS ONE 2024, 19: e0302116. PMID: 39028697, PMCID: PMC11259254, DOI: 10.1371/journal.pone.0302116.Peer-Reviewed Original ResearchConceptsPathways to CareDuration of untreated psychosisManual transcription errorsDevelopment of targeted interventionsReduce duration of untreated psychosisHealthcare accessibility researchReal-time data entryImprove patient outcomesEpisode psychosisCare pathwaysPatient journeyHealthcare contextPatient outcomesPaper-basedConversion of collected dataFEP treatmentData collection processNew HavenData collection methodsData entryTranscription errorsUntreated psychosisOpen-source codebaseData collectionWeb-based toolThe Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program
Ferrara M, Basaldella M, Vacca F, Woods S, Walsh B, Cannon T, Srihari V, Grassi L. The Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program. Early Intervention In Psychiatry 2024, 18: 1040-1046. PMID: 38769052, PMCID: PMC11625525, DOI: 10.1111/eip.13548.Peer-Reviewed Original ResearchClinical high riskFirst-episode psychosisDSM-5-Attenuated Psychosis SyndromeItalian adaptationPsychosis syndromeDSM-5FEP programsEarly stages of psychosisItalian versionFirst-episode psychosis servicesFull-blown psychosisStages of psychosisEpisode of psychosisClinical structured interviewEpisode psychosisEstablished psychosisTrained psychologistsPsychiatric historyPsychosisPsychosis servicesHigh riskStructured interviewsClinical settingEarly detection of individualsAssess validityAntipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration
Szmulewicz A, Martínez-Alés G, Logan R, Ferrara M, Kelly C, Fredrikson D, Gago J, Conderino S, Díaz-Caneja C, Galvañ J, Thorpe L, Srihari V, Yatham L, Sarpal D, Shinn A, Arango C, Öngür D, Hernán M, Collaboration O. Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration. American Journal Of Epidemiology 2024, 193: 1081-1087. PMID: 38576166, DOI: 10.1093/aje/kwae029.Peer-Reviewed Original ResearchFirst-episode psychosisFirst-generation agentsAntipsychotic therapyAntipsychotic drugsPsychosis onsetPsychotic disordersEpisode psychosisAripiprazolePaliperidoneRisk of hospitalizationPsychosisTarget trialsRisperidoneOlanzapineFirst-line therapyTreatment discontinuationEUFESTObservational cohortAntipsychoticsQuetiapineRandomized trialsPrimary outcomeAbsolute riskRisk differenceClinical questionsAccelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needsCorrection: On the proportion of patients who experience a prodrome prior to psychosis onset: a systematic review and meta-analysis
Benrimoh D, Dlugunovych V, Wright A, Phalen P, Funaro M, Ferrara M, Powers A, Woods S, Guloksuz S, Yung A, Srihari V, Shah J. Correction: On the proportion of patients who experience a prodrome prior to psychosis onset: a systematic review and meta-analysis. Molecular Psychiatry 2024, 29: 1567-1567. PMID: 38351175, DOI: 10.1038/s41380-024-02481-0.Peer-Reviewed Original ResearchOn the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis
Benrimoh D, Dlugunovych V, Wright A, Phalen P, Funaro M, Ferrara M, Powers A, Woods S, Guloksuz S, Yung A, Srihari V, Shah J. On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis. Molecular Psychiatry 2024, 29: 1361-1381. PMID: 38302562, DOI: 10.1038/s41380-024-02415-w.Peer-Reviewed Original ResearchSources of heterogeneitySystematic reviewProportion of patientsMeta-analysisSubgroup analysisCochrane Database of Systematic ReviewsDatabase of Systematic ReviewsMeta-analysis of studies of patientsPsychosis onsetProspective cohort studyCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsRegister of Controlled TrialsAPA PsycInfoNarrative synthesisMeta-analysis estimatesCochrane Central RegisterPrevention of psychosisAscertainment methodsWeb of Science Core CollectionRecall biasQualitative studyAssess heterogeneityCohort studyOvid MEDLINEThe impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction
Hazan H, Ferrara M, Riley S, Li F, Zhou B, Kline E, Gibbs-Dean T, Karmani S, Tayfur S, Tek C, Keshavan M, Srihari V. The impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction. Schizophrenia Research 2024, 264: 457-461. PMID: 38266513, PMCID: PMC10923115, DOI: 10.1016/j.schres.2024.01.022.Peer-Reviewed Original ResearchConceptsCoordinated specialty careDuration of untreated psychosisImpact of early detectionEarly detectionEarly detection campaignsSpecialty careAdjustment scoresCampaign yearDetection campaignsMediation analysisEffects of EDRegression modelsCareUntreated psychosisPositive symptomsGAFPatientsSalutary effectsRole of Early Psychosis Detection in the Relationship Between Personal Income and Duration of Untreated Psychosis
Venkataraman S, Hazan H, Li F, Ferrara M, Harper A, Ma J, Shah J, Musket C, Levine N, Keshavan M, Srihari V. Role of Early Psychosis Detection in the Relationship Between Personal Income and Duration of Untreated Psychosis. Psychiatric Services 2024, 75: 427-433. PMID: 38204369, DOI: 10.1176/appi.ps.20230239.Peer-Reviewed Original ResearchDuration of untreated psychosisFirst-episode psychosis servicesFirst-episode psychosisEarly psychosis detectionLow personal incomeSocioeconomic statusUntreated psychosisOutcome of first-episode psychosisLength of duration of untreated psychosisEffectiveness of early detectionSpecialty care clinicsProlonged duration of untreated psychosisReduce duration of untreated psychosisEffects of ageLow socioeconomic statusPersonal incomeIndicators of disparitiesEarly detection effortsAssociated with younger ageYears of educationSES indicatorsCare clinicsEarly detectionBlack raceHierarchical regression
Clinical Trials
Current Trials
Teen Brain and Behavior Study
HIC ID1111009332RoleSub InvestigatorPrimary Completion Date12/21/2022Recruiting ParticipantsGenderBothAge13 years - 17 years
Academic Achievements & Community Involvement
Clinical Care
Overview
Vinod H. Srihari, MD, is a psychiatrist dedicated to improving the outcomes of early course schizophrenia spectrum disorders. His clinical focus involves treating recent onset or 'first-episode' psychosis, often using a combination of medication management and psychosocial interventions designed to stabilize symptoms and promote long-term recovery.
Dr. Srihari also serves as director of the program for Specialized Treatment Early in Psychosis (STEP) at Yale. STEP includes a comprehensive early intervention service and hosts a statewide learning health system that aims to improve access and care for all individuals with recent onset schizophrenia spectrum disorders.
In addition to his clinical work, Dr. Srihari is an active researcher and professor of psychiatry at Yale School of Medicine. His research spans from studies of the causes and mechanisms of schizophrenia to innovative clinical interventions and service-level improvements aimed at enhancing patient outcomes. He is particularly interested in developing tools to help predict how a patient's condition might progress and how to choose the best treatments. He also works on interventions to prevent decline and promote recovery in early psychosis patients.
Dr. Srihari has been instrumental in developing and implementing an evidence-based medicine approach in psychiatric training. This approach enables psychiatrists in training to ask, access, appraise, and apply the best available scientific evidence to their practice, thereby improving patient care and population health.
Dr. Srihari received his medical training from the University of Rochester and completed his residency in psychiatry and a fellowship at Yale School of Medicine.
Clinical Specialties
Psychiatry
Fact Sheets
Schizophrenia
Learn More on Yale Medicine
Yale Medicine News
News & Links
Media
News
- February 11, 2025
Srihari Named Recipient of APA's Gralnick Award for Research in Schizophrenia
- February 13, 2024Source: WNPR
Mindmap 2.0 on Connecticut Public Radio
- February 13, 2024
Mindmap Launches Statewide Campaign to Support Early Detection of First-episode Psychosis in Teens and Young Adults
- October 10, 2023
Riley Appointed Medical Director of STEP Clinic
Get In Touch
Contacts
Mailing Address
Psychiatry
34 Park Street
New Haven, CT 06519
United States
Locations
The STEP Program
Lab
Connecticut Mental Health Center
34 Park Street
New Haven, CT 06519